Literature DB >> 11521170

The effect of high-dose pentaerythritol tetranitrate on the development of nitrate tolerance in rabbits.

J Müllenheim1, S Müller, U Laber, V Thämer, W Meyer, E Bassenge, B Fink, G Kojda.   

Abstract

Experimental studies with therapeutic doses of pentaerythritol tetranitrate (PETN) have shown unexpected actions such as a lack of nitrate tolerance and vasoprotective effects in atherosclerosis. We investigated the effect of a 3-week treatment with low- (6 mg kg(-1) day(-1), n=10) and high-dose (100 mg kg(-1) day(-1), n=10) oral PETN given twice daily on the development of nitrate tolerance in rabbits. We measured aortic relaxation in response to acetylcholine, S-nitroso-N-acetyl-D,L-penicillamine and PETN, constriction in response to phenylephrine and production of reactive oxygen species (ROS). Mean aortic pressure (AOPmean) and heart rate were measured after a single oral dose of PETN (50 mg kg(-1), n=6) and after increasing doses of pentaerythritol dinitrate (PEDN, n=5) and pentaerythritol mononitrate (PEMN, n=5) in anaesthetized rabbits. Oral PETN, even at high dosage, was not associated with nitrate tolerance. None of the aortic ring studies showed a difference in the responses to the vasodilators, while the vasoconstriction to phenylephrine was slightly reduced in both PETN groups. The production of vascular ROS was also not different. Oral PETN reduced AOPmean transiently (-19.3+/-4.4%, P<0.01 vs. controls) and i.v. administration of both PEMN and PEDN reduced AOPmean dose dependently (P<0.05, ANOVA). These results suggest that oral PETN elicits minor nitrate tolerance. This unique feature might be due to the slow onset of vasodilator activity of the predominantly active metabolites PEDN and PEMN and might contribute to the vasoprotective activity of PETN in atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11521170     DOI: 10.1007/s002100100464

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  6 in total

1.  Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1.

Authors:  Swenja Schuhmacher; Philip Wenzel; Eberhard Schulz; Matthias Oelze; Christian Mang; Jens Kamuf; Tommaso Gori; Thomas Jansen; Maike Knorr; Susanne Karbach; Marcus Hortmann; Falk Mäthner; Aruni Bhatnagar; Ulrich Förstermann; Huige Li; Thomas Münzel; Andreas Daiber
Journal:  Hypertension       Date:  2010-02-15       Impact factor: 10.190

2.  Effect of oral organic nitrates on expression and activity of vascular soluble guanylyl cyclase.

Authors:  M Oppermann; V T-V Dao; T Suvorava; M Bas; G Kojda
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

Review 3.  New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance.

Authors:  A Daiber; P Wenzel; M Oelze; T Münzel
Journal:  Clin Res Cardiol       Date:  2007-10-19       Impact factor: 5.460

4.  Sustained Formation of Nitroglycerin-Derived Nitric Oxide by Aldehyde Dehydrogenase-2 in Vascular Smooth Muscle without Added Reductants: Implications for the Development of Nitrate Tolerance.

Authors:  Marissa Opelt; Gerald Wölkart; Emrah Eroglu; Markus Waldeck-Weiermair; Roland Malli; Wolfgang F Graier; Alexander Kollau; John T Fassett; Astrid Schrammel; Bernd Mayer; Antonius C F Gorren
Journal:  Mol Pharmacol       Date:  2018-01-22       Impact factor: 4.436

Review 5.  Organic nitrates and nitrate resistance in diabetes: the role of vascular dysfunction and oxidative stress with emphasis on antioxidant properties of pentaerithrityl tetranitrate.

Authors:  Matthias Oelze; Swenja Schuhmacher; Andreas Daiber
Journal:  Exp Diabetes Res       Date:  2010-12-27

6.  Pharmacological induction of vascular extracellular superoxide dismutase expression in vivo.

Authors:  Marc Oppermann; Vera Balz; Volker Adams; Vu Thao-Vi Dao; Murat Bas; Tatsiana Suvorava; Georg Kojda
Journal:  J Cell Mol Med       Date:  2008-12-24       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.